TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05020015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TAK-007
Description: TAK-007 intravenous injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy Agents
Description: Fludarabine and cyclophosphamide as per standard of care.
Study: NCT04645719

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Lactate ringer group
Description: General anesthesia only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate dose through real weight group
Description: General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's real weight

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium sulfate dose through corrected ideal weight group
Description: General anesthesia + magnesium sulfate 15 mg.kg-1.h-1 based on the patient's corrected ideal weight
Study: NCT06027645

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Crawling stimulation with a mini-skateboard (i.e. the crawliskate)
Description: Consists of 8 weeks of daily training. Infants benefit from a 10 minutes session everyday at home with either a trained therapist or his/her parents. Parents are trained by the therapist at the begining of the 8 weeks. During each session the infant is prone wrapped on a mini-skateboard (i.e. the crawliskate) and has to produce flexion and extension movements with his four limbs in order to move forward with the assistance of the adult (therapist or parent).
Study: NCT06286748

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Beetroot juice
Description: Beetroot juice + exercise. Patients will ingest 200ml of beet juice (Beta vulgaris) containing approximately 300mg of nitrate (NO3-), and after 2 hours they will be instructed to perform an exercise protocol.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo + exercise. Patients will ingest 200ml of placebo (water, without nitrate (NO3-)), and after 2 hours they will be instructed to perform an exercise protocol.
Study: NCT05329935

Intervention type: BIOLOGICAL
Intervention: Cultured Thymus Tissue
Description: Product will be surgically administered into the quadriceps

Intervention type: BIOLOGICAL
Intervention: Cultured Thymus Tissue
Description: Product will be surgically administered into the quadriceps
Study: NCT04622176

Intervention type: DIAGNOSTIC_TEST
Intervention: MMUS
Description: MMUS will be used to perform diagnostics, we will compare with MRI and histology
Study: NCT05948280

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual reality-supported mindfulness
Description: A single mindful stretching exercise provides a conscious stretch of VR scenario. The implementation of VR exercises will be performed by the interventionist who have received training in the application of VR scenarios and have extensive experience in VR research.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness
Description: The interventionist will guide the participant to do a mindful stretching exercise in the first week. During the second week, the interventionist will send participants an audio recording on how to do mindful stretching exercise via WeChat/WhatsApp.
Study: NCT05321836

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucosamine Chondroitin
Description: control group

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: glucosamine chondritin & Physiotherapy
Description: experimental group
Study: NCT04957134

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electro-acupuncture
Description: The acupoints of electro-acupuncture will be selected as Zusanli ,Sanyinjiao ,Zhongwan , Tianshu , Shuifen , Daheng ,Daimai , Shuidao ,Huaroumen and Fujie . We will deliver electrical stimulation with dense-disperse waves at 50 Hz and 10 V through the electrical acupuncture stimulation instrument to the abdominal points. The bodily needles will be retained for 30 minutes . Electro-acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Sham electro-acupuncture
Description: The acupoints of sham electro-acupuncture will be selected as nonacupoints . The internal output power cord of the electrical acupuncture stimulation instrument will be interrupted. The bodily needles will be retained for 30 minutes . Sham acupuncture treatment will be applied 3 times a week, once every other day, for 8 consecutive weeks.
Study: NCT06286189

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Placebo capsule taken 30 min before sleep
Study: NCT05780671

Intervention type: OTHER
Intervention: oxygen
Description: inhaled oxygen 10L/min with face mask for 1 hour
Study: NCT05261269

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAN-222
Description: Administered IV every week to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAN-222
Description: Administered IV every week to subjects

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niraparib
Description: Administered orally once daily
Study: NCT06286189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trazodone Hydrochloride
Description: Trazodone 100 mg 30 min before sleep
Study: NCT05371847

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment for upper limb dysfunction
Description: clinical assessments and questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: assessment for upper limb dysfunction
Description: clinical assessments and questionnaires

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retest assessment
Description: For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: retest assessment
Description: For the test-retest reliability testing, participants will be invited to have an additional appointment approximately 1 week after the main assessment.
Study: NCT06770803

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Low Pressure Pneumoperitoneum
Description: The objective of this trial is to determine whether the maintenance of a low intraperitoneal insufflation pressure (IIP) of ≤10 mmHg during the parenchymal transection phase of conventional and robotic-assisted laparoscopic liver resection is non-inferior to a higher IIP of ≥14 mmHg in terms of intraoperative blood loss, gas embolisms, perioperative morbidity, and mortality.
Study: NCT06771154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adebelimab Combined with Apatinib
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Apatinib, 250 mg, once daily (qd), orally (po). Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adebelimab
Description: Chemotherapy Phase (Total of 6 cycles, each cycle 21 days) Carboplatin AUC 5 mg/mL/min, administered on the first day of each cycle. Paclitaxel 175 mg/m², intravenous infusion for 3 hours, administered on the first day of each cycle.~Adebelizumab, Fixed dose of 1200 mg per administration, on the first day of each cycle, until the end of chemotherapy or until treatment is discontinued due to disease progression, intolerable toxicity, or other reasons specified in the protocol.~Maintenance Therapy Phase (Each cycle 21 days) Adebelimab, Fixed dose of 1200 mg per administration, IV (intravenous), Q3W (every 3 weeks), on the first day of each cycle, for a maximum of two years; Treatment continues until disease progression, intolerable toxicity, or other reasons specified in the protocol result in discontinuation.
Study: NCT06773182

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intermittent Fasting Intervention
Description: A 14:10 intermittent fasting regimen, where participants fast for 14 hours and consume all meals within a 10-hour eating window daily.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet Intervention
Description: A diet emphasizing whole grains, fruits, vegetables, olive oil, lean proteins, and minimizing processed foods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet Intervention
Description: A diet limiting fermentable oligosaccharides, disaccharides, monosaccharides, and polyols to manage gastrointestinal symptoms.
Study: NCT06771531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation
Description: tDCS can safely and selectively modulate cortical excitability (specifically neuronal firing likelihood) by transferring weak electrical currents between scalp electrodes. The direct current delivered by any one electrode will not exceed 2.0 mA and the total amount of current from all electrodes will not exceed 4 mA in this study.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active sham stimulation
Description: sham stimulation will implement the same protocol of the tDCS intervention; however, only very low-level currents (no more than 0.5 mA) are transferred between the same electrodes used for the tDCS throughout the 20-minute session. This strategy effectively mimics the cutaneous sensations and skin redness induced by creating only micro cortical electric fields.
Study: NCT06770244

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: positive psychology-based intervention package
Description: The postpartum depression intervention program will be developed in accordance with the principles of positive psychology, incorporating online psychological interventions as the primary mode of delivery. Specifically, psychological courses and training based on positive psychology will be conducted in addition to the usual community-based primary health care. Interventions use formats that include online videos and supplemental materials. The aim of the intervention is to help pregnant and postpartum women understand mental health, enhance positive emotions, improve negative emotions, maintain interpersonal relationships, and explore life meaning. Additionally, one-on-one online consultations based on positive psychology will be offered to high-risk women.
Study: NCT06770946

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Amniotic Membrane Application
Description: Amniotic Membrane Application:~This intervention involves the application of an amniotic membrane harvested intraoperatively from the fetal side of the placenta during cesarean delivery. The membrane is placed directly on the incision site before surgical closure to promote wound healing and reduce complications such as infection, dehiscence, and scarring. The membrane is removed 24 hours postoperatively, and standard wound care is continued thereafter.
Study: NCT06774027

Intervention type: PROCEDURE
Intervention: Specimen collection
Description: Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

Intervention type: PROCEDURE
Intervention: Specimen collection
Description: Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

Intervention type: PROCEDURE
Intervention: Specimen collection
Description: Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

Intervention type: PROCEDURE
Intervention: Specimen collection
Description: Blood specimens will be collected during regular clinical visits for correlative and exploratory analysis

Intervention type: DRUG
Intervention: Non-Investigational Antibody-Drug Conjugates (ADC)
Description: ADC given under usual care for the treatment of cancer

Intervention type: DRUG
Intervention: Non-Investigational Antibody-Drug Conjugates (ADC)
Description: ADC given under usual care for the treatment of cancer

Intervention type: DRUG
Intervention: Non-Investigational Antibody-Drug Conjugates (ADC)
Description: ADC given under usual care for the treatment of cancer
Study: NCT06110832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-based Meditation and Yoga program
Description: In the mindfulness-based meditation and yoga program, mindfulness-based formal and informal interventions are conducted for 8 weeks.
Study: NCT05738239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser therapy
Description: Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Laser therapy
Description: Biological effects of low-level LASER therapy have been studied for various clinical indications, including musculoskeletal conditions and some acute pain conditions. PBMT includes low level LASER (works on pain) and light-emitting diodes (LED) (works on wound healing).
Study: NCT06401161

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3T Pu'er tea
Description: Two types of Pu-erh tea with different levels of theabrownin content.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 3T Pu'er tea
Description: Two types of Pu-erh tea with different levels of theabrownin content.
Study: NCT06541223

Intervention type: OTHER
Intervention: Standard informed consent procedure
Description: Face-to-face informed consent procedure supported by informational brochure

Intervention type: OTHER
Intervention: Standard informed consent procedure
Description: Face-to-face informed consent procedure supported by informational brochure

Intervention type: OTHER
Intervention: Multimedia video
Description: Multimedia presentation on implant-based reconstruction
Study: NCT05307315

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: listening to music
Description: The experimental group will listen to Turkish instrumental music with headphones for 30 minutes.
Study: NCT06384885

Intervention type: DIAGNOSTIC_TEST
Intervention: Ultrasound
Description: Lung ultrasound
Study: NCT05179317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: Drug: QL1706 Intravenous Infusion~Drug: Paclitaxel injection Intravenous Infusion~Drug: Cisplatin/Carboplatin Intravenous Infusion~Drug:Bevacizumab Intravenous Infusion
Study: NCT03315832

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
Study: NCT06267833

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: exercise
Description: In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: In the exercise protocol, a personalized, home-based, 30-minute Otago exercise program consisting of strength, balance, and walking exercises performed three times a week will be implemented for 8 weeks with home visits and telerehabilitation sessions (via Videoconferencing) under the supervision of the responsible researcher. In addition to the Otago exercise program, trunk and upper extremity exercises (totaling 45 minutes) will be implemented in study group 1 using traditional methods and in study group 2 using the mobile game method.
Study: NCT06067880

Intervention type: OTHER
Intervention: Cancer-related Unilateral
Description: This group included patients who have used only contraction type LVs.

Intervention type: OTHER
Intervention: Normal + Ectasis LVs
Description: This group included patients who had only non- contraction type LVs.
Study: NCT04370327

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pain Free Exercise (PF)
Description: Patients will exercise until the onset on claudication (1 on the rating scale)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate Claudication Pain Exercise (MOD-P)
Description: Patients will exercise until they experience moderate claudication pain (2 on the rating scale)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Maximal Claudication Pain Exercise (MAX-P)
Description: Patients will exercise until they experience maximal claudication pain (4 on the rating scale)
Study: NCT05625776

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: pain delivery with capsaicin and heat
Description: Experimental pain paradigm delivered (capsaicin cream combined with heat) that is short-term and painful but not harmful

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: distractor delivery with sensory TENS
Description: Distractor stimulus delivered (sensory TENS electrical stimulation) that is short-term and attention-demanding but not painful
Study: NCT05201755

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.

Intervention type: DEVICE
Group type: OTHER
Intervention: CPAP
Description: Application of PEEP (positive end-expiratory pressure) through a CPAP Helmet with a set PEEP of 10 cmH2O. It is a very well tolerated and noninvasive device commonly used for ventilatory support.
Study: NCT06151509

Intervention type: DRUG
Group type: OTHER
Intervention: Alpha-Agonist
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.

Intervention type: DRUG
Group type: OTHER
Intervention: α-adrenergic receptor agonist
Description: An initial infusion dose of prophylactic norepinephrine (0.05 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.01 ug/kg/min of prophylactic norepinephrine according to the responses of previous patients according to the up-down sequential allocation.
Study: NCT02926521

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-octyl cyanoacrylate
Description: Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 2-octyl cyanoacrylate
Description: Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Mastic
Description: Addition of gum mastic liquid adhesive to nerve catheter dressing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gum Mastic
Description: Addition of gum mastic liquid adhesive to nerve catheter dressing